---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-085705"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2025-08-29T23:59:59+00:00"
generated_at: "2026-05-17T09:11:50.254437+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Carisma enters $5M subscription deal with Ocugen; Nasdaq deadline extended to Oct 21

## Summary
- Subscription agreement with Ocugen for $5M private placement as part of concurrent $25M financing.
- CEO Steven Kelly amended employment agreement with retention/transaction bonuses contingent on merger closing.
- Nasdaq extends bid price compliance deadline to Oct 21; must complete merger by Oct 7 and show $4 bid price.
- Merger with OrthoCellix must close by Oct 7 for continued listing on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001104659-25-085705
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2025-08-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 5.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465925085705/0001104659-25-085705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465925085705/tm2524685d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-085705
- JSON: https://secwatch.observer/filing/0001104659-25-085705.json
- Plain text: https://secwatch.observer/filing/0001104659-25-085705.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.